Related Experiment Videos
[Thrombolytic therapy of acute myocardial infarct: which drugs? Which patients?]
1II. Internen Abteilung, Kardiologie, Allgemeinen Krankenhauses Wels.
Insights
Thrombolytic therapy for acute myocardial infarction reduces mortality with agents like streptokinase (SK) and APSAC. While rtPA offers higher recanalization, its increased intracranial bleeding risk questions cost-effectiveness.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Context:
- Acute myocardial infarction (AMI) management.
- Established efficacy of thrombolytic agents.
- Ongoing evaluation of reperfusion strategies.
Purpose:
- To review the efficiency of thrombolytic therapy in AMI.
- To compare mortality reduction and recanalization rates of different thrombolytic agents.
- To assess bleeding complications and cost-effectiveness.
Summary:
- Thrombolytic therapy, including streptokinase (SK) and APSAC, reduces mortality in AMI.
- Recombinant tissue plasminogen activator (rtPA) shows higher recanalization but also reocclusion rates.
- Major bleeding is similar across agents, but rtPA may increase intracranial bleeding, impacting cost-effectiveness.
Impact:
- Informs therapeutic strategies for AMI based on clinical trial data.
- Highlights the trade-offs between efficacy and safety of different thrombolytic agents.
- Raises questions about the cost-effectiveness of rtPA in specific patient groups.
Abstract:
The efficiency of thrombolytic therapy in acute myocardial infarction has been documented in a large number of studies. The reduction of mortality has been shown for streptokinase (SK) and APSAC and various combinations (SK and aspirin). The recanalisation-rate is higher for rtPA as is the reocclusion-rate. Major bleeding complications are similar for all agents. However, the incidence of intracranial bleedings seems to be higher with rtPA; thus the cost-effectiveness for the tissue plasminogen activators is questionable. Attempts are made to focus on the implications of the major clinical trials for the therapeutic strategy in different patient-groups.